vs

Side-by-side financial comparison of Astrana Health, Inc. (ASTH) and Primerica, Inc. (PRI). Click either name above to swap in a different company.

Astrana Health, Inc. is the larger business by last-quarter revenue ($950.5M vs $853.7M, roughly 1.1× Primerica, Inc.). Primerica, Inc. runs the higher net margin — 23.1% vs 0.7%, a 22.4% gap on every dollar of revenue. On growth, Astrana Health, Inc. posted the faster year-over-year revenue change (42.9% vs 11.0%). Over the past eight quarters, Astrana Health, Inc.'s revenue compounded faster (53.3% CAGR vs 7.2%).

Astrana Health, Inc. is a U.S.-based value-based healthcare services provider that primarily serves Medicare-eligible senior populations across the United States. It offers in-home primary care, chronic disease management, and care coordination services, aiming to improve patient health outcomes and reduce unnecessary medical costs.

Primerica, Inc. is a multi-level marketing company that provides insurance, investment and financial services to middle-income families in the United States and Canada.

ASTH vs PRI — Head-to-Head

Bigger by revenue
ASTH
ASTH
1.1× larger
ASTH
$950.5M
$853.7M
PRI
Growing faster (revenue YoY)
ASTH
ASTH
+31.9% gap
ASTH
42.9%
11.0%
PRI
Higher net margin
PRI
PRI
22.4% more per $
PRI
23.1%
0.7%
ASTH
Faster 2-yr revenue CAGR
ASTH
ASTH
Annualised
ASTH
53.3%
7.2%
PRI

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ASTH
ASTH
PRI
PRI
Revenue
$950.5M
$853.7M
Net Profit
$6.6M
$197.0M
Gross Margin
Operating Margin
1.9%
28.9%
Net Margin
0.7%
23.1%
Revenue YoY
42.9%
11.0%
Net Profit YoY
184.4%
17.9%
EPS (diluted)
$0.12
$6.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASTH
ASTH
PRI
PRI
Q4 25
$950.5M
$853.7M
Q3 25
$956.0M
$839.9M
Q2 25
$654.8M
$793.3M
Q1 25
$620.4M
$804.8M
Q4 24
$665.2M
$768.8M
Q3 24
$478.7M
$774.1M
Q2 24
$486.3M
$803.4M
Q1 24
$404.4M
$742.8M
Net Profit
ASTH
ASTH
PRI
PRI
Q4 25
$6.6M
$197.0M
Q3 25
$373.0K
$206.8M
Q2 25
$9.4M
$178.3M
Q1 25
$6.7M
$169.1M
Q4 24
$-7.8M
$167.1M
Q3 24
$16.1M
$164.4M
Q2 24
$19.2M
$1.2M
Q1 24
$14.8M
$137.9M
Gross Margin
ASTH
ASTH
PRI
PRI
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
98.0%
Q1 24
98.2%
Operating Margin
ASTH
ASTH
PRI
PRI
Q4 25
1.9%
28.9%
Q3 25
2.0%
32.3%
Q2 25
3.1%
29.6%
Q1 25
3.3%
27.5%
Q4 24
0.1%
64.7%
Q3 24
5.9%
32.9%
Q2 24
6.2%
1.0%
Q1 24
7.5%
24.1%
Net Margin
ASTH
ASTH
PRI
PRI
Q4 25
0.7%
23.1%
Q3 25
0.0%
24.6%
Q2 25
1.4%
22.5%
Q1 25
1.1%
21.0%
Q4 24
-1.2%
21.7%
Q3 24
3.4%
21.2%
Q2 24
3.9%
0.1%
Q1 24
3.7%
18.6%
EPS (diluted)
ASTH
ASTH
PRI
PRI
Q4 25
$0.12
$6.11
Q3 25
$0.01
$6.35
Q2 25
$0.19
$5.40
Q1 25
$0.14
$5.05
Q4 24
$-0.14
$4.92
Q3 24
$0.33
$4.83
Q2 24
$0.40
$0.03
Q1 24
$0.31
$3.93

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASTH
ASTH
PRI
PRI
Cash + ST InvestmentsLiquidity on hand
$429.5M
$756.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$779.3M
$2.4B
Total Assets
$2.2B
$15.0B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASTH
ASTH
PRI
PRI
Q4 25
$429.5M
$756.2M
Q3 25
$463.4M
$644.9M
Q2 25
$342.1M
$621.2M
Q1 25
$260.9M
$625.1M
Q4 24
$290.8M
$687.8M
Q3 24
$350.3M
$550.1M
Q2 24
$327.7M
$627.3M
Q1 24
$337.3M
$593.4M
Stockholders' Equity
ASTH
ASTH
PRI
PRI
Q4 25
$779.3M
$2.4B
Q3 25
$775.5M
$2.3B
Q2 25
$765.5M
$2.3B
Q1 25
$745.4M
$2.3B
Q4 24
$712.7M
$2.3B
Q3 24
$704.6M
$1.9B
Q2 24
$678.9M
$2.1B
Q1 24
$653.5M
$2.2B
Total Assets
ASTH
ASTH
PRI
PRI
Q4 25
$2.2B
$15.0B
Q3 25
$2.2B
$14.8B
Q2 25
$1.4B
$14.8B
Q1 25
$1.3B
$14.6B
Q4 24
$1.4B
$14.6B
Q3 24
$1.3B
$14.8B
Q2 24
$1.3B
$14.6B
Q1 24
$1.2B
$14.9B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASTH
ASTH
PRI
PRI
Operating Cash FlowLast quarter
$-2.9M
$338.2M
Free Cash FlowOCF − Capex
$-6.0M
FCF MarginFCF / Revenue
-0.6%
Capex IntensityCapex / Revenue
0.3%
Cash ConversionOCF / Net Profit
-0.44×
1.72×
TTM Free Cash FlowTrailing 4 quarters
$104.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASTH
ASTH
PRI
PRI
Q4 25
$-2.9M
$338.2M
Q3 25
$10.0M
$202.9M
Q2 25
$90.9M
$162.6M
Q1 25
$16.6M
$197.5M
Q4 24
$-10.9M
$270.6M
Q3 24
$34.0M
$207.3M
Q2 24
$23.2M
$173.3M
Q1 24
$6.0M
$210.9M
Free Cash Flow
ASTH
ASTH
PRI
PRI
Q4 25
$-6.0M
Q3 25
$7.4M
Q2 25
$89.5M
Q1 25
$13.6M
Q4 24
$-13.5M
Q3 24
$31.7M
Q2 24
$20.4M
Q1 24
$5.6M
FCF Margin
ASTH
ASTH
PRI
PRI
Q4 25
-0.6%
Q3 25
0.8%
Q2 25
13.7%
Q1 25
2.2%
Q4 24
-2.0%
Q3 24
6.6%
Q2 24
4.2%
Q1 24
1.4%
Capex Intensity
ASTH
ASTH
PRI
PRI
Q4 25
0.3%
Q3 25
0.3%
Q2 25
0.2%
Q1 25
0.5%
Q4 24
0.4%
Q3 24
0.5%
Q2 24
0.6%
Q1 24
0.1%
Cash Conversion
ASTH
ASTH
PRI
PRI
Q4 25
-0.44×
1.72×
Q3 25
26.69×
0.98×
Q2 25
9.65×
0.91×
Q1 25
2.48×
1.17×
Q4 24
1.62×
Q3 24
2.11×
1.26×
Q2 24
1.21×
147.98×
Q1 24
0.40×
1.53×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASTH
ASTH

Medicare$542.4M57%
Commercial$99.1M10%
Care Delivery$92.1M10%
Care Enablement$78.9M8%
Other Third Parties$58.0M6%
Health Care Patient Service$39.8M4%
Health Care Other$25.5M3%
Other$12.1M1%
Management Service$10.3M1%

PRI
PRI

Revenues From Sources Other Than Contracts With Customers$445.9M52%
Investment And Savings Products Segment Revenues$340.3M40%
Other$56.5M7%
Segment Revenues From Contracts With Customers$11.0M1%

Related Comparisons